Talizumab

Drug Profile

Talizumab

Alternative Names: Anti-IgE monoclonal antibody Hu 901; HU 901; TNX 901

Latest Information Update: 14 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanox
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Peanut hypersensitivity

Most Recent Events

  • 26 Feb 2004 Genentech, Novartis and Tanox, Inc., have settled all litigation among themselves for the development and commercialisation of certain anti-IgE antibodies including Omalizumab and TNX 901
  • 26 Feb 2004 Suspended - Phase-II for Peanut allergy in USA (unspecified route)
  • 12 Mar 2003 Data from the 60th Anniversary Meeting of the American Academy of Allergy and Asthma and Immunology (AAAAI-2003) have been added to the Immunological Disorders therapeutic trials section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top